Melatonin and Chemotherapy in Lung Cancer
Author Information
Author(s): Ghielmini M, Pagani O, Jong J de, Pampallona S, Conti A, Maestroni G, Sessa C, Cavalli F
Primary Institution: Servizio Oncologico Cantonale, Ospedale San Giovanni, 6500 Bellinzona, Switzerland
Hypothesis
Does melatonin have a myeloprotective effect in patients receiving chemotherapy for lung cancer?
Conclusion
Melatonin does not protect against the myelotoxic effects of carboplatin and etoposide in lung cancer patients.
Supporting Evidence
- Melatonin was given at a dose of 40 mg per day for 21 days.
- Patients were randomized to receive melatonin with either the first or second cycle of chemotherapy.
- The study measured haematological parameters three times per week for three weeks.
Takeaway
This study tested if melatonin could help protect patients from the harmful effects of chemotherapy, but it didn't work.
Methodology
Twenty patients with inoperable lung cancer received chemotherapy with carboplatin and etoposide, along with either melatonin or placebo, in a double-blind setup.
Limitations
The study had a small sample size and focused only on specific types of lung cancer.
Participant Demographics
Median age of 60 years, with 16 having non-small cell lung cancer and 4 small-cell lung cancer.
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website